Cancer immunotherapy of breast cancer is currently challenged by low response rates and lack of predictive markers for immune therapies; lack of druggable targets that counteract T cell evasion; and lack of safe and effective target antigens for adoptive T cell therapies. In Part 1 of this thesis (Chapter2-4) we focused on the knowledge gap regarding T cell evasive mechanisms, which, provides a basis for patient stratification and selection of combination therapies. In Part 2 of this thesis (Chapter 5-7) we focused on the identification and selection of safe and effective target antigens and corresponding TCRs for adoptive T cell therapy for TNBC (one of the subtypes of breast cancer
